Proliferative Verrucous Leukoplakia: Risks, Progression, and Care

Proliferative verrucous leukoplakia (PVL) is one of the most aggressive precancerous conditions that can develop in the mouth, distinguished from ordinary white patches (leukoplakia) by its tendency to spread across multiple sites, resist treatment, and transform into cancer at rates far higher than any other oral lesion. It behaves so differently from garden-variety leukoplakia that researchers consider it a separate disease altogether, with its own clinical course, its own frustrating habit of coming back after treatment, and its own demographic profile that skews heavily toward older women.¹ Understanding what makes PVL distinct matters because the window between an innocuous-looking white patch and a full-blown oral cancer can close quietly if the condition is not recognized for what it is.

What Makes PVL Different from Ordinary Leukoplakia

Most white patches inside the mouth are simple leukoplakias. They sit in one spot, they may or may not carry microscopic signs of trouble, and plenty of them never become cancerous. PVL breaks that pattern in almost every way. It starts as a flat white patch, often looking completely harmless under a microscope, but then it spreads. Over months and years, it moves to new areas of the mouth, thickens, develops a bumpy or wart-like surface texture, and eventually progresses through increasingly worrisome tissue changes. The clinical and microscopic characteristics, along with this relentlessly aggressive behavior, are what led researchers to classify PVL as its own entity rather than just a stubborn form of leukoplakia.¹

One of the defining features is multifocality. Proposed diagnostic criteria require involvement of more than two separate areas inside the mouth, a combined lesion size of at least three centimeters, and a documented history spanning at least five years that shows the disease spreading and recurring after treatment.² That time requirement is part of why PVL is notoriously difficult to diagnose early. In its earliest stages, a single flat white patch looks identical to a common, low-risk leukoplakia. Only after the disease has been evolving for years, spreading and returning, does the full picture come into focus. By then, the condition may already be well along its progression.

Who Develops PVL

PVL has a striking demographic pattern that sets it apart from most oral cancers and precancerous conditions. It disproportionately affects older women. In one comparative study, the average age at presentation was about 66.5 years, and women outnumbered men roughly two to one, with patients typically showing lesions in two to six different oral sites.³ This is unusual because most oral cancers are more common in men and are strongly tied to tobacco and alcohol use. PVL frequently appears in people with no traditional risk factors at all, which is one reason it can fly under the radar.

The female predominance is not just a demographic curiosity. A meta-analysis found that in PVL cases that did undergo malignant transformation, women made up about three-quarters of the group and had roughly twice the odds of developing cancer compared to men with PVL.⁴ Why women are more susceptible remains unclear. No hormonal or genetic explanation has been firmly established, and the lack of a clear cause makes it harder to identify who should be screened more closely.

Where PVL Appears in the Mouth

PVL does not limit itself to one favorite spot. A systematic review of clinical manifestations found the gums were the single most common location, involved in about half of cases, followed closely by the inner cheek lining and the tongue.⁵ The alveolar ridge, which is the bony ridge where teeth sit, is also frequently affected.⁶

The gum involvement is clinically important for a practical reason. Lesions nestled between teeth, along the gumline, or in the spaces between the tooth roots are exceptionally difficult to remove surgically without damaging surrounding structures. This anatomical reality is one of the reasons PVL has such high recurrence rates, and it factors heavily into treatment decisions.

How PVL Progresses Toward Cancer

PVL follows a recognizable trajectory, though the speed varies from person to person. It typically begins as a flat, white patch that a pathologist would read as simple thickened tissue with no alarming features. Over time, the surface becomes more textured, developing a bumpy, wart-like, or corrugated appearance. The intermediate and later stages are clinically raised lesions that, under the microscope, show verrucous hyperplasia. From there, many progress into verrucous carcinoma, squamous cell carcinoma, or both.⁷

PVL carries the highest malignant transformation rate of any oral precancerous condition.⁸ This is not a condition where cancer is a remote possibility. For many patients, the question is when transformation will happen, not whether it will. The progression can unfold over years or even decades, which creates a long surveillance burden for both patients and their care teams. Each follow-up biopsy may show a different stage of the disease across different mouth sites simultaneously, making it possible to have harmless-looking patches in one area and early cancer in another at the same time.

The Puzzle of What Causes It

Unlike most oral cancers, PVL has no clearly established cause. Tobacco, the usual suspect for oral malignancies, does not account for the majority of cases. Many PVL patients have never smoked. Early research investigated whether human papillomavirus (HPV) might be a driver. One study testing lesions from PVL patients found HPV DNA in nearly all samples, with HPV type 16 being the most common strain detected.⁹ But subsequent research has been inconsistent, and no consensus exists that HPV is a causative agent rather than a bystander. The virus may colonize already-damaged tissue without being the thing that damaged it in the first place.

At the molecular level, PVL is turning out to have a genetic signature that is distinct from the usual pathways seen in conventional oral squamous cell carcinoma. Systematic reviews of the molecular landscape show that early PVL lesions have high rates of loss of heterozygosity, a genetic event where the cell loses one copy of a gene region, but low levels of the broader chromosomal rearrangements that typically pile up in established cancers. Interestingly, mutations in TP53, the gene most famously associated with cancer development, are not a hallmark of PVL.¹⁰ When PVL does give rise to squamous cell carcinoma, the resulting tumors show infrequent TP53 mutations and different patterns of other cancer-related gene changes compared to cancers that arise through the usual tobacco-driven pathway.¹¹ This suggests PVL follows a distinct biological route to cancer, which is both scientifically fascinating and clinically frustrating because it means treatments targeting the standard molecular culprits may not apply.

Why Diagnosis Takes So Long

One of the most challenging aspects of PVL is that it is essentially a retrospective diagnosis. Clinicians often cannot confirm it until the disease has been evolving for years. The earliest biopsy may show nothing more than mildly thickened tissue. Current diagnostic criteria require evidence of spreading and recurrence over an extended period, which means the disease has to prove itself before the label fits.²

Efforts to standardize how PVL lesions are reported under the microscope have helped somewhat. An expert consensus guideline endorsed by major pathology organizations recommends using three descriptive categories for the tissue changes seen in PVL: a corrugated thickened surface layer that is not simply a reaction to irritation, a bulkier overgrowth of thickened surface tissue, and tissue that is suspicious for or already constitutes squamous cell carcinoma.¹² This framework helps pathologists communicate more clearly with clinicians, but it does not solve the fundamental problem that early PVL looks like many other things.

Some researchers have suggested the name itself needs updating. Because not all PVL lesions develop a verrucous (wart-like) surface, and a meaningful fraction present as mixed red-and-white patches rather than purely white ones, the term “proliferative leukoplakia” has been proposed as a broader and more accurate label. The subset with prominent redness appears to carry a particularly high rate of malignant transformation.¹³ This matters practically because a clinician looking only for white, warty patches could miss cases that present with more redness or a smoother surface.

Telling PVL Apart from Other Mouth Conditions

Several other conditions can produce white or mixed patches inside the mouth, and distinguishing PVL from them is not always straightforward. Oral lichen planus, a chronic inflammatory condition, is one of the most common look-alikes. A comparative study found that lichen planus tends to show a lacy, web-like (reticular) pattern and favors the inner cheeks bilaterally, while PVL tends to present as plaque-like patches. Nearly all PVL patients in the study showed some degree of abnormal cell changes under the microscope, which was a useful distinguishing feature.¹⁴

Other conditions in the differential include conventional leukoplakia, verrucous carcinoma presenting as a standalone lesion, and lichenoid drug reactions. The clinical context matters enormously. A single white patch in a 30-year-old smoker is a very different situation from multifocal white patches spreading across the gums and cheeks of a 65-year-old nonsmoking woman. When the latter pattern emerges, PVL should be high on the list of possibilities.

Treatment and the Recurrence Problem

The standard approach to PVL is surgical removal, either with a traditional scalpel or with laser ablation. These remain the treatments most commonly used.¹⁵ But calling them a “gold standard” overstates the confidence behind them, because the results are sobering. A meta-analysis of recurrence data found that roughly two-thirds of patients who underwent surgical removal or laser treatment experienced the lesion coming back.¹⁶ Many of those recurrences then went on to develop into verrucous carcinoma or squamous cell carcinoma.¹⁷

The anatomy of PVL makes clean removal especially difficult. When lesions involve the gum tissue between teeth, the floor of the mouth, or areas close to sensitive structures like the lingual nerve, the ducts draining saliva glands, or blood vessels beneath the tongue, aggressive surgery risks substantial complications and long-term harm to function.¹⁵ Wide surgical excision of extensive PVL can seriously affect a person’s ability to eat, speak, and swallow, creating quality-of-life consequences that have to be weighed against the cancer risk of leaving the disease partially treated.

This is the central dilemma of PVL care. The disease demands treatment because of its high cancer risk, but the available treatments fail to permanently eliminate it in most cases, and aggressive surgery exacts a heavy functional toll. That tension drives the search for alternatives.

Emerging and Experimental Approaches

Photodynamic therapy (PDT) has attracted interest as a less invasive option. The approach uses a light-sensitizing agent applied to the lesion, followed by exposure to a specific wavelength of light that activates the agent and destroys abnormal tissue. Case reports have described complete resolution of PVL lesions after PDT sessions, with one report documenting no recurrence after 12 months¹⁸ and another showing no recurrence at 20 months after laser-assisted PDT.¹⁹

These results are encouraging but should be interpreted cautiously. Individual case reports are the weakest form of clinical evidence. PVL can take years to recur, so a 12- or 20-month follow-up is a relatively short window for a disease known for its persistence over decades. The thick, keratinized surface of many PVL lesions can also block the light-sensitizing agent from penetrating effectively, which is why some protocols now combine laser pretreatment to thin the surface before applying PDT.¹⁹ Larger, longer-term clinical trials are needed before PDT can be recommended as a reliable alternative to surgery.

Other experimental approaches under investigation include topical immune-modifying agents like imiquimod, which work by stimulating the body’s local immune response against abnormal cells. Early case reports exist, but the evidence base is still thin. No systemic drug therapy has shown consistent effectiveness against PVL.

Field Cancerization and Why Recurrence Is Not Just Bad Luck

One concept that helps explain PVL’s stubborn behavior is field cancerization. This refers to the idea that the entire lining of the mouth in a PVL patient, not just the visible patches, may harbor underlying molecular changes that predispose it to developing new lesions. Research using DNA methylation analysis from brushings of clinically normal-looking tissue on the opposite side of the mouth from a PVL lesion found the same abnormal chemical tagging patterns seen in oral squamous cell carcinoma.²⁰

This finding has real implications for treatment planning. If the entire oral lining is primed for abnormal growth, cutting out one patch does not address the underlying problem. The next lesion is not necessarily a “recurrence” of the old one; it may be a new event arising from already-compromised tissue elsewhere. This is why surveillance in PVL is not optional or time-limited. Patients with this diagnosis generally need regular clinical examinations and periodic biopsies for the rest of their lives.

Research into the oral microbiome, the community of bacteria living in the mouth, has added another layer. A study of the bacterial communities in PVL patients found a loss of microbial diversity and an enrichment of bacterial species associated with disease. While the connection is not yet understood well enough to drive treatment decisions, oral bacterial imbalance has been linked to both general inflammation and the metabolism of potentially cancer-causing chemicals in other contexts.²¹

Salivary Biomarkers and the Hope for Noninvasive Monitoring

Because PVL requires long-term surveillance and repeated biopsies are burdensome, there is strong interest in finding less invasive ways to track whether the disease is progressing. A recent study measured levels of matrix metalloproteinases (MMPs), a family of enzymes involved in tissue breakdown, in the saliva of PVL patients. About six months later, the researchers checked which patients had shown disease progression. Roughly two-thirds had progressed. Among the enzymes tested, a combination of two of them, MMP-3 and MMP-7, predicted progression with about 80% sensitivity and 89% specificity.²²

If validated in larger studies, a saliva test could change how PVL patients are followed. Instead of scheduling biopsies on a fixed calendar, clinicians could use a simple saliva sample to help decide when a biopsy is truly warranted. That would reduce the procedure burden on patients while still catching progression early. This line of research is still in its early stages, but it represents one of the more promising advances in PVL management in recent years.

Living with PVL and What Patients Should Know

If you have been told you have PVL, a few practical realities are worth understanding. First, the diagnosis itself may have taken years to reach. If your clinician is raising PVL as a possibility after a series of recurring white patches, that pattern of recurrence is exactly what defines the condition. Second, no treatment currently eliminates the problem permanently in most people. The goal of treatment shifts from cure to control: removing or reducing visible disease, monitoring for new changes, and catching any malignant transformation as early as possible.

Regular follow-up visits, typically every three to six months depending on disease activity, are the backbone of PVL management. Biopsies will likely be needed repeatedly over the years, especially when a patch changes in appearance, develops redness, or becomes painful. Any new symptom, bleeding, numbness, or difficulty moving the tongue warrants an earlier visit rather than waiting for a scheduled appointment.

Dental care also matters. Because PVL so commonly involves the gums and the tissue around teeth, maintaining good oral hygiene and working closely with a dentist who understands the diagnosis can help with early detection of changes. Some patients benefit from being managed jointly by an oral medicine specialist, an oral and maxillofacial surgeon, and a head-and-neck oncologist, particularly when malignant transformation has already occurred or the disease is widespread. The coordination between these specialists is where care quality often varies the most.